The resurgence of covalent drugs
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Covalent drugs have proved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project. There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium. This review surveys the prevalence and pharmacological advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Covalent inhibitors, also known as irreversible inhibitors, are a class of inhibitors that bind to amino acid residues of target proteins through covalent bonds formed by mildly reactive functional groups to confer additional affinity, compared to that of non-covalent inhibitors, which achieve binding and inhibition of target proteins through non-covalent interactions such as hydrogen bond and van”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [30]
In the citing paper
“Recent improvements in structural biology and chemical reactivity have enabled the design and development of potent and selective covalent PPI inhibitors.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“Aided by recent advancements in structural biology and chemistry, covalent inhibitors have emerged as a potentially effective approach towards PPI inhibition [37, 38].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“In the 1970s, researchers reported that covalent drugs produce hepatotoxicity resulting from off-target effects via unselectively modifying non-target proteins with their highly reactive groups [37, 45].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“The initial binding step (K1) and the subsequent chemical reaction step (kinact) are two important factors determining the selectivity of covalent inhibitors (Fig. 7) [37].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“For example, approximately 50% of patients with non-small-cell lung carcinoma (NSCLC) who initially responded to reversible EGFR inhibitors relapsed owing to the emergence of tumour cells that express EGFR with mutations at T790M and/or L858R in the ATP binding sit”
BackgroundThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“An irreversible mechanism of action also helps to mitigate against competition by high intracellular concentrations of AT”
BackgroundLigand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Targeting proteases: successes, failures and future prospects
Turk, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2092 · Cited by 1,363
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Navigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 952
Cited by
Items 901–1,000 of 1,001
Covalent inhibitor reactivity prediction by the electrophilicity index—in and out of scope
Hermann, M. R., Pautsch, A., Grundl, M. A., Weber, A., & Tautermann, C. S. (2020) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-020-00342-w · Cited by 17
Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma
Hasipek, M., Grabowski, D., Guan, Y., Alugubelli, R. R., Tiwari, A. D., Gu, X., DeAvila, G., Silva, A. S., Meads, M. B., Parker, Y., et al. (2021) · Cancers · doi:10.3390/cancers13112649 · Cited by 19
“Several of the amino acid substitutions, most notably histidine and alanine, were less effective as reflected in the ratio of k2/Ki (Supplemental Table S1), a marker for potency and selectivity [27].”
BackgroundMethodAddressing the Right Targets in Oncology: Challenges and Alternative Approaches
Stock, J. K., Jones, N. P., Hammonds, T. R., Roffey, J., & Dillon, C. (2015) · SLAS DISCOVERY · doi:10.1177/1087057114564349 · Cited by 21
Burcham, P. C., Raso, A., & Kaminskas, L. M. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.078956 · Cited by 21
Selective Covalent Targeting of Pyruvate Kinase M2 Using Arsenous Warheads
Wang, J., Zhou, S., Cheng, Y., Cheng, L., Qin, Y., Zhang, Z., Bi, A., Xiang, H., He, X., Tian, X., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01563 · Cited by 18
New techniques and strategies in drug discovery (2020–2024 update)
Gong, Q., Song, J. H., Song, Y., Tang, K., Yang, P., Wang, X., Zhao, M., Ouyang, L., Rao, L., Yu, B., et al. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110456 · Cited by 19
Slow-Binding and Covalent HDAC Inhibition: A New Paradigm?
Raouf, Y. S., & Moreno–Yruela, C. (2024) · JACS Au · doi:10.1021/jacsau.4c00828 · Cited by 21
Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL‐1
Daressy, F., Malard, F., Séguy, L., Guérineau, V., Apel, C., Dumontet, V., Robert, A., Groo, A., Litaudon, M., Bignon, J. S., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202100011 · Cited by 20
Identification of the first structurally validated covalent ligands of the small GTPase RAB27A
Jamshidiha, M., Lanyon‐Hogg, T., Sutherell, C. L., Craven, G. B., Tersa, M., Vita, E. D., Brustur, D., Pérez‐Dorado, I., Hassan, S., Petracca, R., et al. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00225b · Cited by 19
Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis
Contentti, E. C., & Correale, J. D. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s348129 · Cited by 22
“Conversely, for irreversible inhibitors, short systemic exposure could be sufficient for sustained inhibition, as the pharmacodynamic effect depends on the turnover of the target−inhibitor adduct rather than on exposure duration.(127) The efficacy of BTK inhibitors has been demonstrated in EAE.”
BackgroundTian, L., Qiang, T., Yang, X., Yue, G., Zhai, X., Kang, K., Du, C., Lu, Q., Gao, H., Zhang, D., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115979 · Cited by 20
Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins
Zhang, X., & Cravatt, B. F. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-041946 · Cited by 21
Advancements in Aerogel Technology for Antimicrobial Therapy: A Review
Croitoru, G.-A., Pîrvulescu, D.-C., Niculescu, A.-G., Rădulescu, M., Grumezescu, A. M., & Nicolae, C.-L. (2024) · Nanomaterials · doi:10.3390/nano14131110 · Cited by 21
“The strong attachment of the antimicrobial compounds to the aerogel matrix is ensured by the resulting covalent bonds, which eventually improve their retention and effectiveness [82].”
BackgroundMathiesen, I. R., Calder, E. D. D., Kunzelmann, S., & Walport, L. J. (2024) · Communications Chemistry · doi:10.1038/s42004-024-01388-9 · Cited by 21
“Targeted covalent inhibitors (TCIs) address this by combining weakly electrophilic warheads with high af fi nity scaffolds which optimally position the reactive group to react at a target residue 4,5 .”
Recent Advances in Irreversible Kinase Inhibitors
Gilbert, A. M. (2014) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.14.24 · Cited by 18
Development of Methods for The Bioanalysis of Rrx-001 and Metabolites
Scicinski, J. J., Oronsky, B. T., Cooper, V., Taylor, M., Alexander, M., Hadar, R., Cosford, R., Fleischmann, T., & Fitch, W. L. (2014) · Bioanalysis · doi:10.4155/bio.13.331 · Cited by 18
Potential Strategies for Increasing Drug-Discovery Productivity
Cumming, J. G., Finlay, M. R. V., Giordanetto, F., Hemmerling, M., Lister, T., Sanganee, H. J., & Waring, M. J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.7 · Cited by 20
Probing the mechanism of cardiovascular drugs using a covalent levosimendan analog
Pineda-Sanabria, S. E., Robertson, I. M., Sun, Y., Irving, M., & Sykes, B. D. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.02.003 · Cited by 18
Enantioselective Synthesis and Profiling of Two Novel Diazabicyclooctanone β-Lactamase Inhibitors
Xiong, H., Chen, B., Durand-Réville, T. F., Joubran, C., Alelyunas, Y. W., Wu, D., & Huynh, H. K. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500284k · Cited by 20
Synthesis and Performance of a Biomimetic Indicator for Alkylating Agents
Provencher, P. A., & Love, J. A. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b01584 · Cited by 23
Carboxylic Acid Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Lou, Y. C., & Zhu, J. (2016) · Wiley-VCH eBooks · doi:10.1002/9783527693931.ch16 · Cited by 22
Advances in the synthesis of glycosidic macrolides: clavosolides A–D and cyanolide A
Lee, K., Lanier, M. L., Kwak, J., Kim, H., & Hong, J. (2016) · Natural Product Reports · doi:10.1039/c6np00073h · Cited by 18
Maltais, R., Trottier, A., Roy, J., Ayan, D. P., Bertrand, N., & Poirier, D. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.12.007 · Cited by 20
Selective alkylation of T–T mismatched DNA using vinyldiaminotriazine–acridine conjugate
Onizuka, K., Usami, A., Yamaoki, Y., Kobayashi, T., Hazemi, M. E., Chikuni, T., Sato, N., Sasaki, K., Katahira, M., & Nagatsugi, F. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1278 · Cited by 18
Reversible covalent direct thrombin inhibitors
Sivaraja, M., Pozzi, N., Rienzo, M., Lin, K., Shiau, T. P., Clemens, D. M., Igoudin, L., Zalicki, P., Chang, S., Estiarte, M. A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201377 · Cited by 18
Synthesis and structure–activity relationship studies of MI-2 analogues as MALT1 inhibitors
Wu, G., Wang, H., Zhou, W., Zeng, B., Mo, W., Zhu, K., Liu, R., Zhou, J., Chen, C., & Chen, H. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.04.059 · Cited by 18
“Although traditional drug development has shied away from irreversible inhibitors owing to the safety concerns, the resurgence of covalent drugs with outstanding phamacodynamic properties of MI-2 continues to drive medicinal chemists to discover more effective leads through comprehensive SARs.(30) For example, Overkle…”
BackgroundInfluentialHuang, Y., Wang, S., Leng, J., Moku, B., Zhao, C., Alharbi, N. S., & Qin, H. (2019) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201900799 · Cited by 20
Rational design of a DNA sequence-specific modular protein tag by tuning the alkylation kinetics
Nguyen, T. M., Nakata, E., Zhang, Z., Saimura, M., Dinh, H., & Morii, T. (2019) · Chemical Science · doi:10.1039/c9sc02990g · Cited by 19
Zhu, J., Yu, Q., Cai, Y., Chen, Y., Liu, H., Liang, W., & Jin, J. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00083 · Cited by 18
Isgrò, C., Sardanelli, A. M., & Palese, L. L. (2021) · Viruses · doi:10.3390/v13010106 · Cited by 18
“Interest in covalent drugs has been increasing in recent years, not only in the field of infectious disease treatment [53,54].”
BackgroundApproach for the Design of Covalent Protein Kinase Inhibitors via Focused Deep Generative Modeling
Yoshimori, A., Miljković, F. N., & Bajorath, J. (2022) · Molecules · doi:10.3390/molecules27020570 · Cited by 21
“However, these views have partly changed over the past decade as potential advantages of covalent inhibitors have increasingly been realized if unique or only weakly conserved residues important for the activity of given targets can be modified [5,6], leading to so-called targeted covalent inhibitors (TCIs) [6].”
BackgroundQuantum mechanics approaches to drug research in the era of structural chemogenomics
Ilatovskiy, A. V., Abagyan, R. A., & Kufareva, I. (2013) · International Journal of Quantum Chemistry · doi:10.1002/qua.24400 · Cited by 18
Duplan, V., Serba, C., Conejo-Garcia, J. R., Valot, G., Barluenga, S., Hoerlé, M., Cuendet, M., & Winssinger, N. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob42049c · Cited by 18
CovaDOTS: In Silico Chemistry-Driven Tool to Design Covalent Inhibitors Using a Linking Strategy
Hoffer, L., Sáez‐Ayala, M., Horvath, D., Varnek, A. A., Morelli, X., & Roche, P. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00960 · Cited by 19
Synthetic Methodology-driven Chemical Protein Modifications
Maruyama, K., & Kanai, M. (2019) · Chemistry Letters · doi:10.1246/cl.190652 · Cited by 20
Yang, Y., Shu, Y.-Z., & Humphreys, W. G. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00460 · Cited by 17
Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors
Brauer, N. R., Kempen, A. L., Hernandez, D. E., & Sintim, H. O. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116540 · Cited by 20
Advances in ERK1/2 inhibition: a medicinal chemistry perspective on structure and regulation
Sah, V. K., Singh, A. K., Kumar, A. M., Prajapati, V., Kalsi, A. K., Khalilullah, H., Jaremko, M., Emwas, A.-H. M., Verma, A., & Kumar, P. (2025) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2555510 · Cited by 20
“…underscores a growing interest in covalent inhibition strategies for eRK1/2. with continued advancement, these compounds may offer advantages in durability of response, overcoming resistance, and improved dosing profiles, potentially rejuvenating the field of covalent eRK inhibitor development 80 .”
Protein Ligand Docking in Drug Discovery
Brás, N. F., Cerqueira, N. M. F. S. A., Sousa, S. F., Fernandes, P. A., & Ramos, M. J. (2014) · Springer eBooks · doi:10.1007/978-3-319-09976-7_11 · Cited by 23
Applications of genetic code expansion technology in eukaryotes
Guo, Q.-R., & Cao, Y. J. (2023) · Protein & Cell · doi:10.1093/procel/pwad051 · Cited by 17
“However, the off-target effects of covalent small molecules remain a major hurdle for their development (Singh et al., 2011; Sibaud et al., 2020).”
BackgroundCao, Z., Wang, Q., Neumann, H., & Beller, M. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202410597 · Cited by 18
Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors
Diogo, M. A., Cabral, A. G. T., & de Oliveira, R. B. (2024) · Pathogens · doi:10.3390/pathogens13100825 · Cited by 20
“In recent decades, there has been progress in the field of medicinal chemistry, aiming at developing new covalent drugs for the treatment of cancer, viral infections, metabolic disorders, and gastrointestinal diseases [87,88].”
BackgroundDacomitinib, an emerging HER-targeted therapy for non-small cell lung cancer.
Carpenter, R. L., & Lo, H. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2012.10.09 · Cited by 19
Efficient and Facile Synthesis of Acrylamide Libraries for Protein-Guided Tethering
Allen, C. E., Curran, P. R., Brearley, A. S., Boissel, V., Sviridenko, L., Press, N. J., Stonehouse, J. P., & Armstrong, A. (2015) · Organic Letters · doi:10.1021/ol503486t · Cited by 17
Cheng, A., & Tsai, I. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.08.019 · Cited by 18
Metal-based methods for protein inactivation
Prakash, J., & Kodanko, J. J. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.12.011 · Cited by 17
Waller, D. D., Jansen, G., Golizeh, M., Martel‐Lorion, C., Dejgaard, K., Shiao, T. C., Mancuso, J., Tsantrizos, Y. S., Roy, R., Sébag, M., et al. (2016) · ChemBioChem · doi:10.1002/cbic.201500485 · Cited by 19
Discovery of host-targeted covalent inhibitors of dengue virus
de Wispelaere, M., Carocci, M., Liang, Y., Liu, Q., Sun, E., Vetter, M. L., Wang, J., Gray, N. S., & Yang, P. L. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.12.017 · Cited by 21
Xu, Y., Smith, R., Vivoli, M., Ema, M., Göös, N., Gehrke, S. S., Harmer, N. J., & Wagner, G. K. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.04.006 · Cited by 18
Guarino, C., Gruba, N., Grzywa, R., Dyguda‐Kazimierowicz, E., Hamon, Y., Łęgowska, M., Skoreński, M., Dallet‐Choisy, S., Marchand-Adam, S., Kellenberger, C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01416 · Cited by 18
Borgarelli, C., Klingl, Y. E., Escamilla‐Ayala, A., Munck, S., Bosch, L. V. D., Borggraeve, W. M. D., & Ismalaj, E. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202100296 · Cited by 19
Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma
Zerhouni, M., Martin, A. R., Furstoss, N., Gutierrez, V., Jaune, E., Tekaya, N., Béranger, G. E., Abbe, P., Regazzetti, C., Amdouni, H., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2114 · Cited by 18
Potential of phenothiazines to synergistically block calmodulin and reactivate PP2A in cancer cells
Manoharan, G. B., Okutachi, S., & Abankwa, D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268635 · Cited by 18
“Efforts were made to generate covalently binding derivatives of this compound class, as irreversible binding could significantly increase the potency of drugs [9].”
BackgroundInfluentialdos Santos, A. M., Oliveira, A. R. S., da Costa, C. H. S., Kenny, P. W., Montanari, C. A., Júnior, J. D. J. G. V., & Lameira, J. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00466 · Cited by 18
Development of cell-active non-peptidyl inhibitors of cysteine cathepsins
Dana, D., Davalos, A. R., De, S., Rathod, P., Gamage, R. K., Huestis, J., Afzal, N., Zavlanov, Y., Paroly, S. S., Rotenberg, S. A., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.03.062 · Cited by 18
Mechanism of irreversible inhibition of Mycobacterium tuberculosis shikimate kinase by ilimaquinone
Simithy, J., Fuanta, R., Hobrath, J. V., Kochanowska-Karamyan, A. J., Hamann, M. T., Goodwin, D. C., & Calderón, Á. I. (2018) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2018.04.007 · Cited by 17
Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis
Ramírez, Y. A., Adler, T. B., Altmann, E., Klemm, T., Tiesmeyer, C., Sauer, F., Kathman, S. G., Statsyuk, A. V., Sotriffer, C., & Kisker, C. (2018) · ChemMedChem · doi:10.1002/cmdc.201800364 · Cited by 18
Corso, A. D., Catalano, M., Schmid, A. S., Scheuermann, J., & Neri, D. (2018) · Angewandte Chemie · doi:10.1002/ange.201811650 · Cited by 19
Zhang, Y., Larraufie, M.-H., Musavi, L., Akkiraju, H., Brown, L. M., & Stockwell, B. R. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b01113 · Cited by 16
Bortz, A. R., Bennett, J. M., & Fasan, R. (2024) · Chem · doi:10.1016/j.chempr.2024.08.003 · Cited by 16
The Current Toolbox for Covalent Inhibitors: From Hit Identification to Drug Discovery
You, M., Liu, H., & Li, C. (2025) · JACS Au · doi:10.1021/jacsau.5c01134 · Cited by 24
Soulère, L., Barbier, T., & Queneau, Y. (2021) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2021.107463 · Cited by 19
Comparative reactivity profiling of cysteine-specific probes by chemoproteomics
Yang, F., Chen, N., Wang, F., Jia, G., & Wang, C. (2022) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2022.100024 · Cited by 16
Ultrafast and selective labeling of endogenous proteins using affinity-based benzotriazole chemistry
Xin, X., Zhang, Y., Gaetani, M., Lundström, S. L., Zubarev, R. A., Zhou, Y., Corkery, D., & Wu, Y. (2022) · Chemical Science · doi:10.1039/d1sc05974b · Cited by 21
“Selective chemical labeling of proteins is highly valuable for studying and controlling protein structures, 28 dynamics and functions in vitro and in living systems,(1-9) for development of new materials(10) and for 29 drug development.(11-13) As proteins carry many copies of various functional groups, it is challengi…”
BackgroundModeling receptor flexibility in the structure-based design of KRASG12C inhibitors
Zhu, K., Li, C., Wu, K. Y., Mohr, C., Li, X., & Lanman, B. A. (2022) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-022-00467-0 · Cited by 18
Imberg, L., Platte, S., Erbacher, C., Daniliuc, C. G., Kalinina, S. A., Dörner, W., Poso, A., Kärst, U., & Kalinin, D. V. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00204 · Cited by 16
The Blood-Brain Barrier: Implications for Experimental Cancer Therapeutics
Straehla, J. P., Reardon, D. A., Wen, P. Y., & Agar, N. Y. R. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-040433 · Cited by 17
“Specifically, the abilities to determine and interpret unbound drug fraction (given that protein binding is intrinsic to the mechanism of action) and to accurately classify and quantify metabolites are two challenges being actively investigated in these fields (Singh et al. 2011, Pike et al. 2020).”
BackgroundDoan, N. Q. H., Nguyen, N. T. K., Nguỹên, N. B., Tran, T. T., Tran, Q. N., & Truong, T. N. (2023) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2023.130414 · Cited by 17
Stuart, D. D., Guzman-Perez, A., Brooijmans, N., Jackson, E. L., Kryukov, G. V., Friedman, A. A., & Hoos, A. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0280 · Cited by 21
“Another area of significant progress has been the rational design of covalent small-molecule drugs (87, 88), resulting in more than 40 approved covalent drugs to date.”
BackgroundHu, X., Gong, S., He, Q., Wu, J., & Li, N. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117289 · Cited by 16
Hasan, M. N., Ray, M., & Saha, A. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c04710 · Cited by 17
Recent Advances in Enzyme Inhibition: A Pharmacological Review
Singh, K., Bhushan, B., Mittal, N., Kushwaha, A., Raikwar, C. K., Sharma, A. K., Chanchal, D. K., Kumar, S., & Agrawal, M. (2023) · Current Enzyme Inhibition · doi:10.2174/0115734080271639231030093152 · Cited by 22
Targeted degradation of Pin1 by protein-destabilizing compounds
Alboreggia, G., Udompholkul, P., Rodriguez, I., Blaha, G. M., & Pellecchia, M. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2403330121 · Cited by 18
Computational insights into the suicide inhibition of Plasmodium falciparum Fk506-binding protein 35
MacDonald, C. A., & Boyd, R. J. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.079 · Cited by 16
A tuned affinity-based staurosporine probe for in situ profiling of protein kinases
Cheng, X., Li, L., Uttamchandani, M., & Yao, S. Q. (2014) · Chemical Communications · doi:10.1039/c4cc00184b · Cited by 16
Strategies to Overcome Acquired Resistances Conferred by Mutations in the Kinase Domain of Egfr
Lim, S. M., Jeong, Y., & Hong, S. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0019 · Cited by 17
Trant, J. F., Jain, N., Mazzuca, D. M., McIntosh, J. T., Fan, B., Haeryfar, S. M. M., Lecommandoux, S., & Gillies, E. R. (2016) · Nanoscale · doi:10.1039/c6nr05030a · Cited by 16
Strategies to Overcome Resistance Mutations of Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Liu, L., Shi, B., Wang, X., & Xiang, H. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0145 · Cited by 18
Du, L., Yee, S. S., Karthik, R., & Risinger, A. L. (2020) · Nature Communications · doi:10.1038/s41467-019-14277-w · Cited by 18
Carramiñana, V., de Retana, A. M. O., Palácios, F., & Santos, J. M. D. L. (2020) · Molecules · doi:10.3390/molecules25153332 · Cited by 16
“There is a new renewal of the interest in covalent binding therapeutics due to the FDA support of efficient and innocuous covalent drugs and a better understanding of the benefits of the covalent binding mechanism [33,34].”
Kinetic mechanisms of covalent inhibition
McWhirter, C. L. (2021) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2020.11.001 · Cited by 29
Farhat, N., & Khan, A. U. (2021) · Journal of Molecular Modeling · doi:10.1007/s00894-021-04923-w · Cited by 17
Sabat, M., Dougan, D. R., Knight, B., Lawson, J. D., Scorah, N., Smith, C. R., Taylor, E. R., Vu, P., Wyrick, C., Wang, H., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01026 · Cited by 17
Recent applications of covalent chemistries in protein–protein interaction inhibitors
Chan, A. M., Goodis, C. C., Pommier, E. G., & Fletcher, S. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00112h · Cited by 19
Inhibitors of rhomboid proteases
Wolf, E. V., & Verhelst, S. H. L. (2015) · Biochimie · doi:10.1016/j.biochi.2015.07.007 · Cited by 16
Mechanistic understanding of molecular initiating events (MIEs) using NMR spectroscopy
Sanderson, P. N., Simpson, W., Cubberley, R., Aleksić, M., Gutsell, S. J., & Russell, P. J. (2015) · Toxicology Research · doi:10.1039/c5tx00246j · Cited by 16
Modeling of ribonucleic acid–ligand interactions
Stefaniak, F., Chudyk, E. I., Bodkin, M. J., Dawson, W., & Bujnicki, J. M. (2015) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1226 · Cited by 20
Li, A., Sun, H., Du, L., Wu, X., Cao, J., You, Q., & Li, Y. (2014) · Journal of Molecular Modeling · doi:10.1007/s00894-014-2515-y · Cited by 16
Structural Studies and Anticancer Activity of a Novel Class of β‐Peptides
Kudryavtsev, K. V., Yu, C., Ivantcova, P. M., Polshakov, V. I., Churakov, A. V., Bräse, S., Zefirov, N. S., & Guh, J. (2014) · Chemistry - An Asian Journal · doi:10.1002/asia.201403171 · Cited by 16
Jörg, M., & Scammells, P. J. (2016) · ChemMedChem · doi:10.1002/cmdc.201600066 · Cited by 16
Discovery and characterization of a small‐molecule enteropeptidase inhibitor, SCO ‐792
Sasaki, M., Miyahisa, I., Itono, S., Yashiro, H., Hiyoshi, H., Tsuchimori, K., Hamagami, K., Moritoh, Y., Watanabe, M., Tohyama, K., et al. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.517 · Cited by 16
Biotransformations Leading to Toxic Metabolites
Macherey, A., & Dansette, P. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00025-0 · Cited by 31
Antiproliferative activities of halogenated pyrrolo[3,2-d]pyrimidines
Temburnikar, K. W., Ross, C. R., Wilson, G. M., Balzarini, J. M., Cawrse, B. M., & Seley‐Radtke, K. L. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.06.025 · Cited by 16
Integrated Covalent Drug Design Workflow Using Site Identification by Ligand Competitive Saturation
Yu, W., Weber, D. J., & MacKerell, A. D. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00232 · Cited by 16
“The resurgence of covalent drugs after entering the 21th century was mainly accelerated by the concept of ‘targeted covalent inhibitors’ (TCIs) that combine both covalent and noncovalent components (6, 7).”
3-chymotrypsin-like protease in SARS-CoV-2
Adem, K. A., Ferreira, J. C., Villanueva, A. J., Fadl, S., El-Sadaany, F., Masmoudi, I., Gidiya, Y., Gurudza, T., Cardoso, T. H. S., Saksena, N. K., et al. (2024) · Bioscience Reports · doi:10.1042/bsr20231395 · Cited by 18
“Covalent inhibitors are further classified as peptidomimetic or non-peptide small molecule inhibitors that form strong and specific covalent bonds with their target [124].”
Methods for kinetic evaluation of reversible covalent inhibitors from time-dependent IC 50 data
Mader, L. K., & Keillor, J. W. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00050e · Cited by 20
“6,16 Interestingly, all FDA-approved drugs of this type also display time-dependent inhibition, 13,17 – 21 where the final equilibrium between free enzyme and covalently bound enzyme is slow to establish.”
Chen, P., Sun, J., Zhu, C., Tang, G., Wang, W., Xu, M., Xiang, M., Zhang, C., Zhang, Z., Gao, L., et al. (2022) · Angewandte Chemie · doi:10.1002/ange.202203878 · Cited by 17
Rapid Covalent Labeling of Membrane Proteins on Living Cells Using a Nanobody–Epitope Tag Pair
Cabalteja, C. C., Sachdev, S., & Cheloha, R. W. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00334 · Cited by 14
Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets
Lee, J., & Park, S. B. (2022) · Pharmaceuticals · doi:10.3390/ph15121478 · Cited by 17
“This alt rnative class of th rapeutics called “targeted covalent inhibit rs” (TCIs) was proposed by Singh and co-workers in 2011 [7].”
BackgroundInfluentialBarkan, D. T., Garland, K., Zhang, L., Eastman, R. T., Hesse, M. J., Knapp, M. S., Ornelas, E., Tang, J., Cortopassi, W. A., Wang, Y., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01404 · Cited by 16
Metadata
- Authors
- Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A.
- Affiliations
- University of Washington (US)
- Boston University (US)
- Corresponding author
- Singh, Juswinder
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04
- Volume
- 10
- Issue
- 4
- Pages
- 307-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2010993054
- Cited by
- 1,873
- References
- 71
- Citations by year
- 2026: 136 · 2025: 150 · 2024: 148 · 2023: 137 · 2022: 145 · 2021: 162 · 2020: 152 · 2019: 98 · 2018: 132 · 2017: 125 · 2016: 141 · 2015: 96 · 2014: 81 · 2013: 85 · 2012: 66
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM094551)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- covalent inhibitors, drug safety, covalent drug design, targeted covalent inhibitors
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Structure-Activity Relationship, Drug Design, Drug Delivery Systems, Drug Discovery, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.